Skip to main content
Premium Trial:

Request an Annual Quote

Did You Double-Check that Sequence?

Bosco at the Trapped in the U.S.A. blog wants to know if you've ever made a protein sequencing error. If you ever have, you probably know at little about how the researchers at now-defunct biotech company Genetics Institute felt when they realized that three errors out of 166 amino acids in the protein sequence of erythopoietin, or Epo, cost them $2 billion in lost income and a very valuable patent. Bosco tells the story of the race between Genetics Institute and Amgen to find the correct sequence for Epo — but whereas Amgen was working with Leroy Hood, Genetics Institute's researchers found themselves struggling to figure out why nothing they were doing was working. By the time they figured it out, Amgen had won the race. Amgen got FDA approval for EPO in 1989, and it's now worth $2 billion in income, or about half of Amgen's income in 2002, Bosco says. "Amgen became a biotech behemoth, whereas Genetics Institute eventually got bought out by Wyeth. And all because of of 3 errors in the sequencing of the protein," he adds.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.